{"id":70723,"date":"2026-05-12T09:57:27","date_gmt":"2026-05-12T09:57:27","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70723"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"kisspeptin-10","status":"publish","type":"product","link":"https:\/\/medsbase.com\/fr\/product\/kisspeptin-10\/","title":{"rendered":"Kisspeptine-10"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">R\u00e9ponse rapide \u2014 Qu'est-ce que la Kisspeptine-10 ?<\/h3>\n<p style=\"margin: 0;\"><strong>Kisspeptine-10<\/strong> (KP-10) is a 10-amino-acid C-terminally amidated peptide and the most-studied active fragment of the KISS1 gene product. It is the apical endogenous regulator of GnRH neuronal activity \u2014 published studies established it as the upstream switch that initiates puberty and drives pulsatile gonadotropin release. Acts via the GPR54 (KISS1R) G-protein-coupled receptor. Supplied in 5\u00a0mg and 10\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Ce que vous obtenez avec MedsBase :<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/fr\/reviews\/\">avis clients<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Chaque commande est couverte par notre <a href=\"https:\/\/medsbase.com\/fr\/medsbase-re-shipment-assurance-policy\/\"><strong>Politique de R\u00e9exp\u00e9ditions Garanties<\/strong><\/a> \u2014 si votre colis n'arrive pas dans les 20 jours ouvrables, nous le r\u00e9exp\u00e9dions.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Sp\u00e9cification<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">D\u00e9tail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Num\u00e9ro CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">374675-21-5 (kisspeptine-10, humaine)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Formule mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>63<\/sub>H<sub>83<\/sub>N<sub>17<\/sub>O<sub>14<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Masse mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1302.45 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>S\u00e9quence<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH<sub>2<\/sub> (YNWNSFGLRF-NH<sub>2<\/sub>, 10 acides amin\u00e9s ; fragment actif amid\u00e9 en C-terminal de la kisspeptine mature de 54 aa)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forme<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Poudre lyophilis\u00e9e (blanche \u00e0 blanc cass\u00e9)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Puret\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599 % (v\u00e9rifi\u00e9 par HPLC, COA sur demande)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Stockage<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilis\u00e9 : 2\u20138 \u00b0C (r\u00e9frig\u00e9rateur) pour le stock de travail ; \u221220 \u00b0C pour le stockage \u00e0 long terme des flacons non ouverts. Reconstitu\u00e9 : 2\u20138 \u00b0C, \u00e0 utiliser dans ~30 jours. Prot\u00e9ger de la lumi\u00e8re. Ne pas congeler-d\u00e9congeler la solution reconstitu\u00e9e.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilit\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Eau bact\u00e9riostatique (recommand\u00e9e) ou eau st\u00e9rile pour des fen\u00eatres d'utilisation plus courtes<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Qu'est-ce que la Kisspeptine-10 ?<\/h2>\n<p><strong>Kisspeptine-10<\/strong> (KP-10) is a 10-amino-acid peptide and the most extensively studied active fragment of the KISS1 gene product, a 145-amino-acid preprokisspeptin that is processed into the 54-amino-acid mature kisspeptin and several shorter C-terminal active fragments (kisspeptin-14, kisspeptin-13, kisspeptin-10). All of the shorter fragments share the C-terminal 10-residue active core and have comparable potency at the kisspeptin receptor \u2014 kisspeptin-10 is the shortest fully active form and is by far the most common peptide in the kisspeptin literature. The well-characterised sequence is YNWNSFGLRF-NH<sub>2<\/sub>, poids mol\u00e9culaire 1302.45 Da, formule empirique C<sub>63<\/sub>H<sub>83<\/sub>N<sub>17<\/sub>O<sub>14<\/sub>. L'amidation en C-terminal est essentielle pour une activit\u00e9 compl\u00e8te du r\u00e9cepteur. KISS1 a \u00e9t\u00e9 initialement identifi\u00e9 comme un g\u00e8ne suppresseur de m\u00e9tastases par Lee et al. (Cancer Res 1996) et a \u00e9t\u00e9 renomm\u00e9 kisspeptine en l'honneur de Hershey, Pennsylvanie (berceau des chocolats Hershey\u2019s Kisses) o\u00f9 le g\u00e8ne a \u00e9t\u00e9 clon\u00e9 pour la premi\u00e8re fois. Le r\u00f4le reproducteur \u2014 KISS1\/GPR54 comme r\u00e9gulateur apical des neurones GnRH et gardien mol\u00e9culaire de la pubert\u00e9 \u2014 a \u00e9t\u00e9 \u00e9tabli par deux articles ind\u00e9pendants en 2003 (Seminara et al., NEJM ; de Roux et al., PNAS) d\u00e9montrant que les mutations perte de fonction de GPR54 causent l'hypogonadisme hypogonadotrope idiopathique chez l'homme. La kisspeptine-10 est fournie sous forme de poudre lyophilis\u00e9e de haute puret\u00e9 pour reconstitution avec de l'eau bact\u00e9riostatique. Elle est <strong>non approuv\u00e9<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use, although ongoing IVF and infertility is investigating clinical applications. <\/p>\n<h2>M\u00e9canisme d'action \u2014 Signalisation GPR54\/KISS1R et l'axe HPG<\/h2>\n<p>What makes kisspeptin-10 mechanistically distinctive among reproductive-peptides is its position as the <strong>r\u00e9gulateur apical en amont<\/strong> of the entire hypothalamic-pituitary-gonadal (HPG) axis. The peptide acts at a single receptor \u2014 GPR54 (also called KISS1R) \u2014 but the downstream cascade controls the full reproductive endocrine system in published studies:<\/p>\n<ul>\n<li><strong>Activation de GPR54 (KISS1R) sur les neurones \u00e0 GnRH<\/strong> \u2014 La kisspeptine-10 se lie \u00e0 GPR54, un r\u00e9cepteur coupl\u00e9 aux prot\u00e9ines G de classe A exprim\u00e9 dens\u00e9ment sur les corps cellulaires des neurones \u00e0 GnRH dans les noyaux arqu\u00e9s hypothalamiques et p\u00e9riventriculaires ant\u00e9rov\u00e9ntraux. L'activation du r\u00e9cepteur couple \u00e0 G\u03b1<sub>q\/11<\/sub> et \u00e0 la phospholipase C, augmentant le calcium intracellulaire et d\u00e9clenchant la d\u00e9polarisation des neurones \u00e0 GnRH et la lib\u00e9ration pulsatile de GnRH dans le syst\u00e8me porte hypophysaire. C'est le m\u00e9canisme le plus direct \u2014 le d\u00e9clenchement des neurones \u00e0 GnRH est l'\u00e9tape limitante de l'activit\u00e9 de l'axe HPG, et la kisspeptine est le principal stimulus endog\u00e8ne.<\/li>\n<li><strong>R\u00e9gulation pulsatile vs en mode surge de l'axe HPG<\/strong> \u2014 Kisspeptin neurons in the arcuate nucleus drive the pulsatile GnRH\/LH pattern that maintains gonadal function throughout adult reproductive life. A separate population of kisspeptin neurons in the anteroventral periventricular nucleus (in rodents) generates the preovulatory LH surge in females. Studies using selective stimulation or knockout of these populations has dissected the two modes of HPG-axis output in published studies.<\/li>\n<li><strong>Initiation de la pubert\u00e9 et le \u201c commutateur kisspeptine \u201d<\/strong> \u2014 Loss-of-function GPR54 mutations cause complete failure of puberty onset in humans and animal models; gain-of-function mutations cause central precocious puberty. The &#8220;kisspeptin switch&#8221; hypothesis \u2014 that puberty is initiated when arcuate kisspeptin neurons reach a critical activity threshold \u2014 is the dominant model of pubertal onset in current reproductive neuroscience studies.<\/li>\n<\/ul>\n<p>Kisspeptin-10 has a relatively short plasma half-life (~5\u201310 minutes) due to rapid proteolytic cleavage, particularly at the central RF amide motif by matrix metalloproteinases. Subcutaneous, intravenous, and intracerebroventricular routes are all documented in published studies; the central route is reserved for mechanism-of-action studies in rodents where the BBB-crossing question is relevant. For systemic HPG-axis studies, peripheral administration produces measurable GnRH\/LH responses within minutes of bolus injection. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Kisspeptin-10 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Endocrinologie de la reproduction et pharmacologie de l'axe HPG<\/strong> \u2014 dynamique pulsatile de GnRH\/LH\/FSH, r\u00e9gulation par r\u00e9troaction gonadique, r\u00e9troaction des st\u00e9ro\u00efdes sexuels sur l'activit\u00e9 des neurones \u00e0 kisspeptine (Seminara et al., NEJM 2003 ; de Roux et al., PNAS 2003)<\/li>\n<li><strong>Puberty studies<\/strong> \u2014 chronologie du d\u00e9clenchement pubertaire dans les mod\u00e8les rongeurs, mod\u00e8les d'activation des neurones \u00e0 kisspeptine durant la transition pubertaire, analyse m\u00e9canistique de la pubert\u00e9 pr\u00e9coce centrale<\/li>\n<li><strong>Hypogonadotropic hypogonadism studies<\/strong> \u2014 preclinical models of GPR54 loss-of-function, kisspeptin-replacement protocols, mechanism-of-action studies for novel hypogonadism therapies<\/li>\n<li><strong>IVF and ovulation induction studies<\/strong> \u2014 alternatives to hCG trigger in IVF protocols, comparative LH-surge induction; clinical translation has reached Phase 2 in some studies programmes although kisspeptin-10 itself is not approved<\/li>\n<li><strong>Polycystic ovary syndrome (PCOS) studies<\/strong> \u2014 altered kisspeptin tone in PCOS preclinical models, LH-pulse frequency abnormalities, follicular maturation studies<\/li>\n<li><strong>Suppression des m\u00e9tastases et biologie du cancer<\/strong> \u2014 KISS1 was originally identified as a metastasis-suppressor gene; published studies continues to investigate kisspeptin&#8217;s anti-metastatic activity in breast, melanoma, and pancreatic cancer models<\/li>\n<li><strong>Cardiovascular and metabolic support<\/strong> \u2014 expression \u00e9mergente de KISS1R sur les cardiomyocytes et les cellules \u03b2 pancr\u00e9atiques ; effets sur l'hom\u00e9ostasie du glucose et la contractilit\u00e9 cardiaque en cours d'investigation<\/li>\n<li><strong>Comparative reproductive peptide studies<\/strong> \u2014 \u00e9valuation comparative contre <a href=\"https:\/\/medsbase.com\/fr\/pt-141\/\">PT-141 (Bremelanotide)<\/a> for melanocortin-axis sexual-behaviour studies and against <a href=\"https:\/\/medsbase.com\/fr\/oxytocin-acetate\/\">Ac\u00e9tate d'ocytocine<\/a> pour les points finaux affiliatifs et de lien social.<\/li>\n<\/ul>\n<p>Pour un contexte plus large sur la place de la kisspeptine-10 dans le paysage des peptides reproductifs et actifs sur le SNC, voir <a href=\"https:\/\/medsbase.com\/fr\/pt-141\/\">PT-141<\/a> (melanocortin agonist for sexual behaviour studies), <a href=\"https:\/\/medsbase.com\/fr\/oxytocin-acetate\/\">Ac\u00e9tate d'ocytocine<\/a> (neuropeptide du comportement affiliatif), et <a href=\"https:\/\/medsbase.com\/fr\/sermorelin\/\">Sermorelin<\/a> (GHRH-axis hypothalamic-pituitary studies). Browse the full <a href=\"https:\/\/medsbase.com\/fr\/peptides\/\">catalogue de peptides<\/a> pour les compos\u00e9s associ\u00e9s. <\/p>\n<h2>Forces et concentrations disponibles<\/h2>\n<p>MedsBase stocks Kisspeptin-10 in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Concentration du flacon<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Cas d'utilisation typique<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tailles de conditionnement<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 pilot dosing, HPG-axis pulse protocols, single-cohort studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocoles \u00e0 cycle prolong\u00e9, \u00e9tudes \u00e0 cohortes multiples, co\u00fbt le plus bas par mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful when users want to minimise injection volume in rodent protocols. Because kisspeptin-10 dose ranges are in the low-microgram regime per administration, a single 5\u00a0mg vial supports many weeks of pulse-protocol use at typical doses. <\/p>\n<h2>Comparaison \u2014 Kisspeptine-10 vs PT-141<\/h2>\n<p>Kisspeptine-10 et <a href=\"https:\/\/medsbase.com\/fr\/pt-141\/\">PT-141 (Bremelanotide)<\/a> are both small CNS-active peptides used in reproductive- and sexual-behaviour studies, but they act on fundamentally different pathways. Kisspeptin-10 acts on the endocrine HPG axis at the GnRH-neuron level; PT-141 acts on the melanocortin behavioural-sexual axis at the MC4R level. The two are mechanistically complementary rather than competing in study models. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e8re<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Kisspeptine-10<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">PT-141 (Bremelanotide)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Longueur<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 acides amin\u00e9s (d\u00e9capeptide)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">7 acides amin\u00e9s (heptapeptide cyclique)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>R\u00e9cepteur principal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GPR54 \/ KISS1R<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">R\u00e9cepteurs des m\u00e9lanocortines MC3R \/ MC4R<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Effet principal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Lib\u00e9ration de GnRH\/LH\/FSH (endocrinien)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Comportement sexuel m\u00e9di\u00e9 par le SNC (comportemental)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Studies domain<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Axe HPG, pubert\u00e9, hypogonadisme, FIV<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">D\u00e9sir sexuel, excitation, fonction \u00e9rectile<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Demi-vie plasmatique<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~5\u201310 min<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~2 heures (voie SC)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Utilisation clinique approuv\u00e9e<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">None (Phase 2 in IVF studies)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">FDA-approved as Vyleesi for HSDD (different molecule from pharmaceutical-grade)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dose typique<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u2013200 mcg, en bolus ou en pulsation<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">0,25\u20132 mg, administration unique<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The two peptides address different layers of reproductive biology \u2014 kisspeptin-10 the endocrine HPG axis, PT-141 the CNS-mediated behavioural axis \u2014 so they are not direct alternatives. Studies interested in pulsatile GnRH\/LH dynamics, puberty timing, or hypogonadism uses kisspeptin-10. Studies interested in CNS-mediated sexual-arousal pathways uses PT-141. <\/p>\n<h2>Stockage et reconstitution<\/h2>\n<p><strong>Avant la reconstitution :<\/strong> Conservez les flacons lyophilis\u00e9s au r\u00e9frig\u00e9rateur entre 2 et 8 \u00b0C dans leur emballage d'origine pour un stock de travail \u00e0 court terme. Pour un stockage \u00e0 long terme non ouvert, congelez \u00e0 \u221220 \u00b0C. La kisspeptine-10 lyophilis\u00e9e est stable sous r\u00e9frig\u00e9ration jusqu'\u00e0 24 mois et \u00e0 \u221220 \u00b0C jusqu'\u00e0 36 mois. \u00c9vitez les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation de la poudre lyophilis\u00e9e. <strong>Proc\u00e9dure de reconstitution :<\/strong> inject bacteriostatic water down the side wall of the peptide vial (not directly onto the lyophilized cake). For a 5\u00a0mg vial, 2.0\u00a0mL of bacteriostatic water yields a 2.5\u00a0mg\/mL working concentration \u2014 0.04\u00a0mL delivers a 100\u00a0mcg dose. For lower-dose work, further dilution into bacteriostatic water (with optional BSA carrier protein at 0.1%) can be used. Swirl gently \u2014 do <strong>re\u00e7oit pas<\/strong> secouer \u2014 et laisser 2 \u00e0 5 minutes pour une dissolution compl\u00e8te. Une solution correctement reconstitu\u00e9e doit \u00eatre claire et incolore. <strong>Apr\u00e8s reconstitution :<\/strong> Conservez au r\u00e9frig\u00e9rateur entre 2 et 8 \u00b0C et utilisez dans les 30 jours pour une stabilit\u00e9 optimale. Ne congelez pas la solution reconstitu\u00e9e \u2014 les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation d\u00e9gradent l'int\u00e9grit\u00e9 du peptide. Jetez tout flacon pr\u00e9sentant de la turbidit\u00e9, un pr\u00e9cipit\u00e9 ou une d\u00e9coloration. La kisspeptine-10 est sensible au clivage prot\u00e9olytique au niveau du motif RF-amide C-terminal ; la solution reconstitu\u00e9e doit \u00eatre utilis\u00e9e rapidement dans les 30 jours pour les protocoles n\u00e9cessitant un \u00e9talonnage pr\u00e9cis de la dose-r\u00e9ponse. <\/p>\n<h2 id=\"faqs\">Questions fr\u00e9quemment pos\u00e9es<\/h2>\n<h3>What is Kisspeptin-10 used for in studies?<\/h3>\n<p>Kisspeptin-10 is used in studies investigating the hypothalamic-pituitary-gonadal (HPG) axis, GnRH neuron activity, pulsatile gonadotropin release, puberty onset, hypogonadotropic hypogonadism, polycystic ovary syndrome (PCOS), IVF and ovulation-induction alternatives to hCG, cancer metastasis suppression (KISS1 was originally identified as a metastasis-suppressor gene), and emerging cardiometabolic kisspeptin signalling. It is the canonical tool for KISS1R \/ GPR54 pharmacology. The pharmaceutical-grade kisspeptin-10 sold here is <strong>re\u00e7oit pas<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>En quoi la Kisspeptine-10 diff\u00e8re-t-elle du PT-141 ?<\/h3>\n<p>Both are small CNS-active reproductive peptides, but they target different receptors and biological layers. Kisspeptin-10 acts on the GPR54\/KISS1R receptor on GnRH neurons and drives the endocrine HPG axis (LH, FSH, gonadal steroid production). PT-141 acts on MC3R\/MC4R melanocortin receptors in the CNS and drives behavioural-sexual responses (desire, arousal, erectile function). The two are mechanistically complementary and address different studies questions. <\/p>\n<h3>Quelle est la diff\u00e9rence entre la Kisspeptine-10 et la Kisspeptine-54 ?<\/h3>\n<p>Both are active fragments of the KISS1 gene product. Kisspeptin-54 (also called metastin) is the full-length mature 54-amino-acid peptide secreted in vivo. Kisspeptin-10 is the C-terminal 10-amino-acid active core, which retains essentially full receptor potency and is the most commonly used peptide because its smaller size makes synthesis cheaper, purity easier to verify, and reconstitution simpler. Kisspeptin-13 and kisspeptin-14 are intermediate cleavage products that also share the active C-terminal core. All four have comparable potency at GPR54. <\/p>\n<h3>What is the typical Kisspeptin-10 dose?<\/h3>\n<p>Published preclinical protocols typically use 10\u2013200\u00a0mcg per administration in rodent models, given subcutaneously or intravenously for bolus-pulse studies, or as continuous infusion for chronic-stimulation studies. Human IVF has used 6.4\u201312.8\u00a0\u03bcg\/kg as a single subcutaneous trigger dose. A 5\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL \u2014 0.04\u00a0mL equals 100\u00a0mcg. <\/p>\n<h3>La Kisspeptine-10 est-elle approuv\u00e9e par la FDA ?<\/h3>\n<p>No. Kisspeptin-10 is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. Phase 2 clinical studies in IVF ovulation induction is ongoing, but kisspeptin-10 has not been approved for any clinical indication. <\/p>\n<h3>Comment la Kisspeptine-10 doit-elle \u00eatre stock\u00e9e ?<\/h3>\n<p>Flacons lyophilis\u00e9s : r\u00e9frig\u00e9r\u00e9s \u00e0 2\u20138 \u00b0C pour les stocks de travail \u00e0 court terme, ou \u00e0 \u221220 \u00b0C pour le stockage \u00e0 long terme des flacons non ouverts. Solution reconstitu\u00e9e : r\u00e9frig\u00e9r\u00e9e \u00e0 2\u20138 \u00b0C, \u00e0 utiliser dans les 30 jours. Ne pas congeler la solution reconstitu\u00e9e \u2014 les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation d\u00e9gradent le peptide. Prot\u00e9ger de la lumi\u00e8re directe en permanence. Pour les dilutions de travail \u00e0 faible concentration, une prot\u00e9ine porteuse de BSA (0,1 %) est recommand\u00e9e pour minimiser les pertes par adsorption. <\/p>\n<h3>Comment reconstituer la Kisspeptine-10 ?<\/h3>\n<p>Suivez la proc\u00e9dure de reconstitution ci-dessus. Ajoutez de l'eau bact\u00e9riostatique le long de la paroi du flacon (pas directement sur la poudre lyophilis\u00e9e), agitez doucement et laissez reposer 2 \u00e0 5 minutes pour une dissolution compl\u00e8te. Ne <strong>re\u00e7oit pas<\/strong> Secouez le flacon. Une solution correctement reconstitu\u00e9e est claire et incolore. Pour un flacon de 5 mg + 2,0 mL de diluant, la concentration de travail est de 2,5 mg\/mL. <\/p>\n<h3>Quelles sont les dosages disponibles chez MedsBase ?<\/h3>\n<p>MedsBase carries Kisspeptin-10 in 5\u00a0mg and 10\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Pourquoi le g\u00e8ne KISS1 a-t-il \u00e9t\u00e9 initialement nomm\u00e9 kisspeptine ?<\/h3>\n<p>Le g\u00e8ne KISS1 a \u00e9t\u00e9 d\u00e9couvert comme un g\u00e8ne suppresseur de m\u00e9tastases par Lee et al. \u00e0 Hershey, en Pennsylvanie (Cancer Res 1996). Le nom \u201c kisspeptine \u201d \u00e9tait une r\u00e9f\u00e9rence humoristique aux Hershey's Kisses, les chocolats embl\u00e9matiques produits dans la m\u00eame ville. Le r\u00f4le reproductif n'a \u00e9t\u00e9 caract\u00e9ris\u00e9 qu'en 2003 avec la publication simultan\u00e9e d'\u00e9tudes sur l'hypogonadisme par mutation du GPR54 humain dans le NEJM (Seminara et al.) et le PNAS (de Roux et al.). Le peptide a ainsi la particularit\u00e9 inhabituelle d'avoir \u00e9t\u00e9 caract\u00e9ris\u00e9 ind\u00e9pendamment \u00e0 la fois comme un suppresseur de m\u00e9tastases canc\u00e9reuses et comme le r\u00e9gulateur apical de la pubert\u00e9 \u2014 deux r\u00f4les qui restent incompl\u00e8tement connect\u00e9s sur le plan m\u00e9canistique. <\/p>\n<h3>Does Kisspeptin-10 cause side reported effects?<\/h3>\n<p>Published preclinical and Phase 1\/2 clinical studies has documented good tolerability at typical doses. The predominant on-target effects are HPG-axis activation \u2014 rising LH, FSH, testosterone (males) or estradiol (females), and downstream gonadal steroid effects. Off-target findings include modest cardiovascular effects mediated by KISS1R expression on vascular tissue, and a flushing\/vasodilation effect noted in some human studies at higher doses. Long-term safety data outside contexts is limited. <\/p>\n<h3>Quelle est la demi-vie de la Kisspeptine-10 ?<\/h3>\n<p>In preclinical and clinical studies, kisspeptin-10 has a plasma half-life of approximately 5\u201310 minutes following intravenous or subcutaneous administration. The short half-life is due to rapid proteolytic cleavage by matrix metalloproteinases at the central RF-amide motif. For chronic-stimulation studies, continuous infusion or repeated pulse-dosing protocols are used to maintain receptor occupancy. <\/p>\n<h3>How long does Kisspeptin-10 take to show effects in preclinical studies?<\/h3>\n<p>Acute LH responses to bolus kisspeptin-10 administration are detectable within 5\u201315 minutes in rodent and human studies. FSH and downstream gonadal steroid responses develop over hours to days. Chronic-stimulation effects on puberty timing in young rodent models manifest over the natural pubertal window \u2014 days to weeks depending on species and developmental stage at intervention. <\/p>\n<h3>Puis-je commander de la Kisspeptine-10 pour une exp\u00e9dition internationale ?<\/h3>\n<p>Oui. MedsBase exp\u00e9die la Kisspeptine-10 dans le monde entier depuis notre r\u00e9seau d\u00e9di\u00e9 d'exp\u00e9dition de peptides. Les commandes contenant uniquement des peptides sont \u00e9ligibles pour notre service d'exp\u00e9dition d\u00e9di\u00e9 aux peptides. Toutes les commandes sont exp\u00e9di\u00e9es dans un emballage \u00e0 temp\u00e9rature contr\u00f4l\u00e9e avec suivi complet et sont couvertes par notre <a href=\"https:\/\/medsbase.com\/fr\/medsbase-re-shipment-assurance-policy\/\">Politique de R\u00e9exp\u00e9ditions Garanties<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Reproductive, CNS, and Behavioural Studies<\/h2>\n<ul>\n<li><a href=\"\/fr\/pt-141\/\"><strong>PT-141 (Bremelanotide)<\/strong><\/a> \u2014 Cyclic heptapeptide melanocortin agonist \u2014 CNS-mediated sexual-behaviour studies<\/li>\n<li><a href=\"\/fr\/oxytocin-acetate\/\"><strong>Ac\u00e9tate d'ocytocine<\/strong><\/a> \u2014 9-aa cyclic neuropeptide \u2014 social-bonding and affiliative behavioural support<\/li>\n<li><a href=\"\/fr\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 GHRH(1-29) analog \u2014 hypothalamic-pituitary-axis studies<\/li>\n<li><a href=\"\/fr\/cjc-1295-with-dac\/\"><strong>CJC-1295 avec DAC<\/strong><\/a> \u2014 Long-acting GHRH analog \u2014 growth-axis studies<\/li>\n<li><a href=\"\/fr\/selank\/\"><strong>Selank<\/strong><\/a> \u2014 Anxiolytic heptapeptide \u2014 GABA \/ BDNF stress resilience<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Pour en savoir plus<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore reproductive and CNS-active peptides<\/strong><\/p>\n<p style=\"margin: 0;\">Parcourez toute la <a href=\"https:\/\/medsbase.com\/fr\/peptides\/\"><strong>catalogue de peptides<\/strong><\/a>, avec des compos\u00e9s apparent\u00e9s incluant <a href=\"https:\/\/medsbase.com\/fr\/pt-141\/\">PT-141 (Bremelanotide)<\/a> for melanocortin sexual-behaviour studies, <a href=\"https:\/\/medsbase.com\/fr\/oxytocin-acetate\/\">Ac\u00e9tate d'ocytocine<\/a> for affiliative-behaviour studies, and <a href=\"https:\/\/medsbase.com\/fr\/sermorelin\/\">Sermorelin<\/a> for hypothalamic-pituitary-axis studies.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 R\u00e9gulateur apical de l'activit\u00e9 des neurones \u00e0 GnRH<br \/>\n\u2705 Agoniste du r\u00e9cepteur KISS1R \/ GPR54<br \/>\n\u2705 HPG-axis &amp; puberty compound<br \/>\n\u2705 IVF and ovulation-induction studies<br \/>\n\u2705 Initialement identifi\u00e9 comme suppresseur de m\u00e9tastase<\/p>\n<p><strong>Kisspeptine-10<\/strong> contient un compos\u00e9 peptidique synth\u00e9tique.<\/p>","protected":false},"featured_media":70963,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6277,5441],"class_list":["post-70723","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-kisspeptin","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product\/70723","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/comments?post=70723"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media\/70963"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media?parent=70723"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_brand?post=70723"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_cat?post=70723"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_tag?post=70723"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}